Metabolic & Cardiometabolic · Gut & Microbiome
microbiota-derived DPP-4-like activity degrades active GLP-1
In plain terms: Can gut bacteria break down your appetite-suppressing hormone GLP-1?
Yes — the mechanism is consistent, but shown mostly in mice; the human contribution is unmeasured.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
Some gut bacteria carry DPP-4-like activity capable of degrading incretins, and DPP-4-inhibitor drugs reshape the microbiota — but this is mouse/ex-vivo and the human contribution of microbial vs host DPP-4 is unquantified.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Grammatiki M, Tsekmekidou X, Koufakis T, Kotsa K 2026 · Nutrients | observational | mixed | low | Narrative review: diet-microbiota DPP-4-modulating effects influence residual endogenous GLP-1. |
| Jeong N, Chuang LH, Ho Y 2025 · Frontiers in clinical diabetes and healthcare | observational | supports | moderate | Scoping review (52 studies): periodontopathic bacteria, notably P. gingivalis, produce DPP-4-like enzymes that degrade GLP-1, disrupting glucose regulation; host+microbial DPP-4 linked to periodontal inflammation and systemic insulin resist |
| Aljumaah MR, Roach J, Hu Y, Gunstad J, Azcarate-Peril MA 2025 · Sci Adv | observational | supports | moderate | Science Advances review: 'This review discusses the significance of mDPP-4 and its health implications'; the claim-relevant finding is cited, not generated: 'mDPP-4 decreased active GLP-1 activity and disrupted glucose homeostasis ... while GLP-1 activity was not affected in control mice (3).' Review, zero weight. |
| Yasuda T, Harada N, Inagaki N 2024 · J Diabetes Investig | observational | supports | low | Commentary on Wang et al.: oral microbial DPP-4 lowered active GLP-1 and worsened glucose tolerance in high-fat-fed mice. |
| Brockmann L, Ronda C, Schwanz LT, Qu Y, Shneider DW, Mavros CF, Ivanov II, Bhagat G, Wang HH 2025 · Sci Adv | animal | mixed | moderate | Engineered probiotic restored GLP-1 signaling and ameliorated fiber-deficiency effects, implicating microbial modulation of GLP-1. |
| Alanazi M, Al-Kuraishy HM, Mohamed AA, Abass SA, Shokr MM, Alruwaili M, Batiha GE 2026 · Curr Nutr Rep | mechanism | supports | low | Alanazi 2026 review DPP-4/microbiota axis; narrative no new data |
| Petersen N, Greiner TU, Torz L, Bookout A, Gerstenberg MK, Castorena CM, Kuhre RE 2022 · Metabolites | observational | mixed | low | Review microbial DPP-4-like activity degrading incretins; narrative |
| Silva-Veiga FM, Miranda CS, Vasques-Monteiro IML, Souza-Tavares H, Martins FF, Daleprane JB, Souza-Mello V 2022 · World J Gastroenterol | animal | tested-null | low | DPP-4 inhibition plus PPAR-alpha targeted gut dysbiosis, linking microbiota to DPP-4 activity and incretin handling. |
| Olivares M, Hernández-Calderón P, Cárdenas-Brito S, Liébana-García R, Sanz Y, Benítez-Páez A 2024 · Genome Biol | in-vitro | supports | high | Microbial DPP4-like genes increased in human T2D - first human-association layer beyond mouse |
| Kamath S, Chan NSL, Joyce P 2026 · Br J Clin Pharmacol | observational | mixed | low | Review: bidirectional GLP-1 agonist-gut-microbiome relationship; microbial enzymes implicated in incretin/GLP-1 turnover. |
| Trapanese V, Dagostino A, Natale MR, Giofrè F, Vatalaro C, Melina M, Cosentino F, Sergi S, Imoletti F, Spagnuolo R, Arturi F 2025 · Life (Basel) | observational | mixed | low | Review: bidirectional gut microbiota-incretin interactions, with microbial enzymes modulating GLP-1 degradation and DPP-4 activity. |
| Olivares M, Neyrinck AM, Pötgens SA, Beaumont M, Salazar N, Cani PD, Bindels LB, Delzenne NM 2018 · Diabetologia | animal | supports | moderate | Olivares 2018 mice gut microbiota has DPP-4-like activity. ANIMAL, human unquantified |
| Smits MM, Fluitman KS, Herrema H, Davids M, Kramer MHH, Groen AK, Belzer C, de Vos WM, Cahen DL, Nieuwdorp M, van Raalte DH 2021 · Diabetes (Diabète Métab) | RCT | tested-null | moderate | 12-wk RCT: liraglutide/sitagliptin did not change microbiota composition, arguing against a strong drug-microbiome-DPP4 loop. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.